TARRYTOWN, N.Y., June 16, 2021 /PRNewswire/ --
UK RECOVERY investigators found REGEN-COV reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response (primary outcome for the primary analysis population)
First trial to demonstrate that any antibody treatment improved survival in patients hospitalized with COVID-19
Regeneron will share new data with regulatory authorities immediately and request that the U.S. EUA be expanded to include appropriate hospitalized patients
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today welcomed positive results from the largest trial assessing any... More